Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
OwnerVictor V. Sevastyanovinventor
Life of this patent
Estimating the term…
Abstract
A method for treating sensorineural hearing loss caused by different factors, such as hyperbilirubinemia, birth injuries, viral and bacterial infections, ototoxic medications, Usher's syndrome, craniocerebral trauma with a fracture of the base of the scull and the pyramid of the temporal bone, and neurinomas. The method includes administering donepezil hydrochloride (ARICEPT®) in a dosage of 2.5 to 5 mg for an adult, one to two times a day, for 3 to 15 courses of treatment of 20-25 days each. For a child, the dosage is reduced to a range of 0.625 to 1.25 mg.
Claims8
A method for treating sensorineural hearing loss of various genesis, comprising the step of administering an agent, which comprises donepezil hydrochloride (ARICEPT®).
A method for treating sensorineural hearing loss, comprising the step of administering donepezil hydrochloride (ARICEPT®) in a dosage of 2.5 to 5 mg, one to two times a day, for 3 to 5 courses of treatment of 20 to 25 clays each.
A method for treating sensorineural hearing loss, comprising the step of administering donepezil hydrochloride (ARICEPT®) in a dosage of 0.625 to 1.25 mg, one to two times a day, for 3 to 15 courses of treatment of 20 to 25 days each.
Dependencies are inferred from the claim text.